Characterization of Kelch domain‑containing protein 7B in breast tumours and breast cancer cell lines

Martín-Pardillos,Ana; Ramón Y Cajal,Santiago

doi:10.3892/ol.2019.10672

Characterization of Kelch domain‑containing protein 7B in breast tumours and breast cancer cell lines

Authors:
- Ana Martín-Pardillos
- Santiago Ramón Y Cajal
View Affiliations

Affiliations: Translational Molecular Pathology Group, Oncology Department, Vall d'Hebron Institut de Recerca, Edificio Collserola, Hospital Vall d'Hebron, 08035 Barcelona, Spain
Published online on: July 26, 2019 https://doi.org/10.3892/ol.2019.10672
Pages: 2853-2860
Copyright: © Martín-Pardillos et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adenocarcinomas exhibit great heterogeneity, with many genetic and epigenetic alterations. The Kelch domain‑containing protein 7B (KLHDC7B) has recently been identified as epigenetically modified and upregulated in breast cancer. The potential reversibility of epigenetic states offers exciting possibilities for novel cancer diagnostics and drugs. However, to properly evaluate specific inhibitors, the role of KLHDC7B in the development and progression of breast cancer should be established. With that objective in mind, the present study investigated a series of human breast tumours and correlated their clinicopathology, according to the Elston‑Ellis modification of the Scarff‑Bloom‑Richardson (SBR) grading system, with KLHDC7B mRNA expression, analysed using quantitative PCR (qPCR). The results revealed that KLHDC7B was significantly upregulated in grade 3 tumours, and that KLHDC7B expression varied according to the tumour grade and the individual, being downregulated in well‑differentiated and moderately‑differentiated tumours (grade 1‑2) and upregulated in poorly‑differentiated tumours (grade 3). Immunohistochemical staining revealed that ductal tumours and tumours with a higher percentage of Ki67 positive cells showed the highest levels of KLHDC7B. Receptor expression, HER, p53 status, presence of metastasis, and vascular invasion showed no association with KLHDC7B expression. Previous studies have proposed KLHDC7B as an epigenetic marker of breast cancer. We propose that KLHDC7B should be used as a marker for poorly‑differentiated tumours only; use of KLHDC7B without considering tumour grade could lead to an inaccurate diagnosis. Finally, we suggest the appropriate breast cancer cell lines to use to determine the functions of KLHDC7B. KLHDC7B expression was tested in the non‑tumour cell line MCF‑10A and in the breast cancer cell lines MCF‑7, MDA‑MB‑231 and MDA‑MB‑468, using qPCR and western blotting. The results revealed that all tested cancer cell lines overexpressed KLHDC7B mRNA, but MDA‑MB‑468 exhibited a much lower level of protein expression relative to mRNA. Although the breast cancer cell lines used may be appropriate for studying KLHDC7B epigenetic status, MDA‑MB‑468 should be excluded from functional experiments.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P: Cancer incidence in five continents. 9. IARC Press; Lyon, France: 2007
3	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
5	Guo P, You JO, Yang J, Jia D, Moses MA and Auguste DT: Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm. 11:755–765. 2014. View Article : Google Scholar : PubMed/NCBI
6	Elston CW and Ellis IO: Assessment of histological grade. The breast. 13. Churchill Livingstone; Edinburgh-New York: pp. 356–384. 1998
7	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
8	Leal JF, Fominaya J, Cascón A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon Y Cajal S, Robledo M, et al: Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene. 27:1961–1970. 2008. View Article : Google Scholar : PubMed/NCBI
9	López-Vicente L, Armengol G, Pons B, Coch L, Argelaguet E, Lleonart M, Hernández-Losa J, de Torres I, Ramon Y and Cajal S: Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors. Clin Cancer Res. 15:4546–4553. 2009. View Article : Google Scholar : PubMed/NCBI
10	López-Vicente L, Pons B, Coch L, Teixidó C, Hernández-Losa J, Armengol G, Ramon Y and Cajal S: RSK4 inhibition results in bypass of stress-induced and oncogene-induced senescence. Carcinogenesis. 32:470–476. 2011. View Article : Google Scholar : PubMed/NCBI
11	Rowinsky EK: Signal events: Cell signal transduction and its inhibition in cancer. Oncologist (3 Suppl 8). S5–S17. 2003. View Article : Google Scholar
12	Wade PA: Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin. Hum Mol Genet. 10:693–698. 2001. View Article : Google Scholar : PubMed/NCBI
13	Zhang J, Wu LY, Zhang XS and Zhang S: Discovery of co-occurring driver pathways in cancer. BMC Bioinformatics. 15:2712014. View Article : Google Scholar : PubMed/NCBI
14	Schones DE and Zhao K: Genome-wide approaches to studying chromatin modifications. Nat Rev Genet. 9:179–191. 2008. View Article : Google Scholar : PubMed/NCBI
15	Jones PA, Issa JP and Baylin S: Targeting the cancer epigenome for therapy. Nat Rev Genet. 17:630–641. 2016. View Article : Google Scholar : PubMed/NCBI
16	Hutchinson L: Breast cancer: Challenges, controversies, breakthroughs. Nat Rev Clin Oncol. 7:669–670. 2010. View Article : Google Scholar : PubMed/NCBI
17	Kim TW, Kim YJ, Lee HJ, Min SY, Kang HS and Kim SJ: Hs.137007 is a novel epigenetic marker hypermethylated and up-regulated in breast cancer. Int J Oncol. 36:1105–1111. 2010. View Article : Google Scholar : PubMed/NCBI
18	Khirade MF, Lal G and Bapat SA: Derivation of a fifteen gene prognostic panel for six cancers. Sci Rep. 5:132482015. View Article : Google Scholar : PubMed/NCBI
19	Jeong G, Bae H, Jeong D, Ham J, Park S, Kim HW, Kang HS and Kim SJ: A Kelch domain-containing KLHDC7B and a long non-coding RNA ST8SIA6-AS1 act oppositely on breast cancer cell proliferation via the interferon signaling pathway. Sci Rep. 8:129222018. View Article : Google Scholar : PubMed/NCBI
20	Guo P, Wang D, Wu J, Yang J, Ren T, Zhu B and Xiang Y: The landscape of alternative splicing in cervical squamous cell carcinoma. Onco Targets Ther. 8:73–79. 2014. View Article : Google Scholar : PubMed/NCBI
21	NCBI Unigene: Hs.137007-Kelch domain containing 7B (KLHDC7B). http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?UGID=150709&TAXID=9606&SEARCH=Hs.137007December. 2018
22	Hung-Chun Y: Comparative and functional genomics study of the telomeric 7.73-Mb region from marker D22S418 through D22S1726 on human chromosome 22. UMI Dissertations Publishing. 2008.ISBN 9780549576495 (pag 74, 75).
23	NCBI Reference Sequence: Kelch domain-containing protein 7B [Homo sapiens]. https://www.ncbi.nlm.nih.gov/protein/NP_612442December. 2018
24	Laird PW: Cancer epigenetics. Hum Mol Genet. 1:R65–R76. 2005. View Article : Google Scholar
25	Nabilsi NH, Broaddus RR and Loose DH: DNA methylation inhibits p53-mediated survivin repression. Oncogene. 28:2046–2050. 2009. View Article : Google Scholar : PubMed/NCBI
26	Cox GS, Gutkin DW, Haas MJ and Cosgrove DE: Isolation of an Alu repetitive DNA binding protein and effect of CpG methylation on binding to its recognition sequence. Biochim Biophys Acta. 1396:67–87. 1998. View Article : Google Scholar : PubMed/NCBI
27	Dobbelstein M and Moll U: Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov. 13:179–196. 2014. View Article : Google Scholar : PubMed/NCBI
28	Issa JP: DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 13:1634–1637. 2007. View Article : Google Scholar : PubMed/NCBI
29	UniProtKB: Q96G42 (KLD7B_HUMAN), . http://www.uniprot.org/uniprot/Q96G42December. 2018
30	Hara T, Ishida H, Raziuddin R, Dorkhom S, Kamijo K and Miki T: Novel kelch-like protein, KLEIP, is involved in actin assembly at cell-cell contact sites of Madin-Darby canine kidney cells. Mol Biol Cell. 15:1172–1184. 2004. View Article : Google Scholar : PubMed/NCBI
31	Stogios PJ and Privé GG: The BACK domain in BTB-kelch proteins. Trends Biochem Sci. 29:634–637. 2004. View Article : Google Scholar : PubMed/NCBI
32	Mantzouranis L, Bagattini R and Souza GM: KeaA, a Dictyostelium Kelch-domain protein that regulates the response to stress and development. BMC Dev Biol. 10:792010. View Article : Google Scholar : PubMed/NCBI
33	Taguchi K, Motohashi H and Yamamoto M: Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 16:123–140. 2011. View Article : Google Scholar : PubMed/NCBI
34	Gupta VA and Beggs AH: Kelch proteins: Emerging roles in skeletal muscle development and diseases. Skelet Muscle. 4:112014. View Article : Google Scholar : PubMed/NCBI
35	Sesé M, Fuentes P, Esteve-Codina A, Béjar E, McGrail K, Thomas G, Aasen T, Ramón Y and Cajal S: Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signaling and malignant features in vitro and in vivo. Oncotarget. 8:114856–114876. 2017. View Article : Google Scholar : PubMed/NCBI
36	Hevir N, Trošt N, Debeljak N and Rižner TL: Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines. Chem Biol Interact. 191:206–216. 2011. View Article : Google Scholar : PubMed/NCBI
37	Woods Ignatoski KM, Dziubinski ML, Ammerman C and Ethier SP: Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells. Neoplasia. 7:788–798. 2005. View Article : Google Scholar : PubMed/NCBI
38	Lim LY, Vidnovic N, Ellisen LW and Leong CO: Mutant p53 mediates survival of breast cancer cells. Br J Cancer. 101:1606–1612. 2009. View Article : Google Scholar : PubMed/NCBI
39	Dai X, Cheng H, Bai Z and Li J: Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 8:3131–3141. 2017. View Article : Google Scholar : PubMed/NCBI
40	Jiang G, Zhang S, Yazdanparast A, Li M, Pawar AV, Liu Y, Inavolu SM and Cheng L: Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 7 (Suppl 17):S5252016. View Article : Google Scholar
41	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
42	Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M and Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer. 71:3926–3931. 1993. View Article : Google Scholar : PubMed/NCBI
43	van Diest PJ, van der Wall E and Baak JP: Prognostic value of proliferation in invasive breast cancer: A review. J Clin Pathol. 57:675–681. 2004. View Article : Google Scholar : PubMed/NCBI
44	Patani N, Martin LA and Dowsett M: Biomarkers for the clinical management of breast cancer: International perspective. Int J Cancer. 133:1–13. 2013. View Article : Google Scholar : PubMed/NCBI
45	Li CI, Uribe DJ and Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 93:1046–1052. 2005. View Article : Google Scholar : PubMed/NCBI
46	Gry M, Rimini R, Strömberg S, Asplund A, Pontén F, Uhlén M and Nilsson P: Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics. 10:3652009. View Article : Google Scholar : PubMed/NCBI